EGFR and non-small cell lung carcinoma: Based on the IC50 values of the drugs tested on both cell lines, acenocoumarol and silodosin were chosen for furtherin vitro analysis to evaluate their efficacy in treating NSCLC and their antagonistic activity, computationally predicted to bind to allosteric sites of EGFR.